Monoclonal antibody · Degrader of immunoglobulin E · developed by Lycia Therapeutics
LCA-0061 is an antibody-based therapeutic that selectively binds immunoglobulin E (IgE) and rapidly clears it through targeted degradation. It is being studied in atopic disease and peanut allergy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07701954 | Phase 1 | Atopic Disease | Recruiting | LYCA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atopic DiseasePeanut Allergies
Updated Nov 1, 2026. Something wrong or missing? Report it on the LYCA page.
See LYCA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LYCA catalysts and pipeline →